Molecular Diagnostics

News on lab-developed tests and emerging diagnostic technologies.

The company's test volume during the quarter shrank to just over 1,000 samples compared to 1,405 in the same period last year.

The company had no Q2 revenues and continues to advance DetermaVu, its liquid biopsy lung cancer diagnostic test, toward commercialization.

A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.

The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.

The company is continuing to work with a financial advisor to evaluate strategic options, with discussions about potential transactions ongoing.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.